Monopoly Economics: Bayer's Cipro and the 2001 Anthrax Scare
This paper examines the characteristics of a monopoly market through the real-world case of Bayer's patent-protected drug Cipro during the 2001 anthrax letter crisis. It defines the key features of a monopoly — single-firm dominance, high barriers to entry, and monopoly rent pricing — and applies them to the Cipro market. The paper analyzes how the anthrax panic shocked demand and reduced price elasticity, how the U.S. and Canadian governments responded differently to Bayer's monopoly, and how the market eventually returned to equilibrium. The case demonstrates the resilience of patent-enforced monopolies even under extreme short-term disruptions.
- Introduction to Monopoly Markets: Overview of market types and monopoly focus
- Characteristics of a Monopoly: Single seller, barriers to entry, profit maximization
- The Cipro Market Under Normal Conditions: Cipro pricing and demand before 2001 crisis
- Market Disruption During the 2001 Anthrax Crisis: Demand shock, price elasticity, and monopoly cracks
- Restoration of Monopoly Equilibrium: Courts restore patents; market returns to equilibrium
- Conclusion: Patent Protection and Long-Term Monopoly Stability: Patent monopolies proven resilient under extreme conditions
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It grounds abstract economic theory in a concrete, well-known real-world event, making concepts like price elasticity and barriers to entry immediately tangible.
- It uses a comparative lens — contrasting the U.S. and Canadian government responses — to illustrate how monopoly protections can be challenged and restored.
- The paper systematically checks the Cipro market against a defined list of monopoly characteristics, providing a structured and verifiable argument.
Key academic technique demonstrated
The paper uses a case study method to test theoretical economic concepts against empirical events. By applying a checklist of monopoly characteristics to the Cipro market before, during, and after the anthrax crisis, the author demonstrates how market theory predicts and explains real-world behavior — including deviations from expected monopolist conduct such as Bayer's reluctance to raise prices during peak demand.
Structure breakdown
The paper opens with a brief overview of market types and narrows to the monopoly. It then defines monopoly characteristics in sequence — single seller, barriers to entry, profit maximization, and demand elasticity. The central section applies these concepts to the Cipro case chronologically: pre-crisis equilibrium, the 2001 demand shock, monopoly disruption, and eventual restoration. The conclusion synthesizes the case findings to argue that patent protection creates durable pharmaceutical monopolies resistant to long-term disruption.
Introduction to Monopoly Markets
Of the four major market types — monopoly, oligopoly, monopolistic competition, and perfect competition — the latter is the most difficult to truly achieve. Almost as difficult, however, is the monopoly. Monopolies are defined by a certain set of criteria and are expected to behave in a certain way. This paper analyzes the concept of the monopoly in the context of a monopoly on anthrax prevention. The monopoly in question was granted to German drug maker Bayer for its Cipro product. The issue of patent-enforced monopolies was raised during the 2001 anthrax scare, and it can be examined with particular clarity because the U.S. and Canadian governments took different approaches to Bayer's monopoly on anthrax treatment.
Characteristics of a Monopoly
The first characteristic of a monopoly is that there is only one firm in the industry. This firm is the single seller of a good for which there is no substitute (Investopedia, 2009). In the case of Cipro in 2001, there were no competing treatments for anthrax. There were no reasonable substitutes, since the disease responds only to that one drug.
A monopoly should also have high barriers to entry. True monopolies not only face no competition — they have little fear of ever facing competition. In Bayer's case, it held patent protection on Cipro, which provided the company with a monopoly on anthrax prevention in 2001. This is standard in the pharmaceutical industry, because the cost of developing new drugs is high. Pharmaceutical companies, being rational investors, will only develop drugs if they can recoup those costs. Patent protection gives drug companies the ability to turn a profit on their research and development by allowing them the opportunity to earn monopoly rents on the product.
As with all businesses, a monopolist will seek to maximize profit. The monopolist's ability to earn profits is determined by the total demand for the product and the price elasticity of demand. If a product is in high demand and that demand is price inelastic, then the company can raise prices to very high levels. For most products, however, there is some degree of price elasticity of demand (Mercer, 1996). This means that if the price increases too much, demand will fall. For every product, there will be a theoretical demand floor — the minimum demand regardless of price — and a demand ceiling, the total demand if the good were free.
A monopoly is therefore only able to maximize profits if the price stays within the elastic range of the demand curve (AmosWeb, 2009).
The Cipro Market Under Normal Conditions
Under normal circumstances, Cipro was a product with relatively low demand. Incidences of anthrax infection were low, and the drug's harsh side effects capped demand to those with an immediate need to treat an anthrax infection. Bayer was able to price Cipro at a high level, which allowed it to earn monopoly rents on the relatively slow-selling product.
Conclusion: Patent Protection and Long-Term Monopoly Stability
Most pharmaceutical markets are given patent protections that allow those markets to become monopolies for the patent owner. The Cipro case illustrates that even under extremely unusual conditions, the long-term equilibrium will be difficult to disrupt. Short-term cracks appeared in the monopoly, with the expected impact on Bayer's pricing policy, but the long-term implications were relatively minimal. Supply, demand, and price were quickly restored — evidence that a monopoly exists in this and other similarly protected pharmaceutical markets, specifically because of the patent protection.
Always verify citation format against your institution’s current style guide requirements.